Six Months After China Put BCI in Its Government Report: From Lab to Operating Table
A couple of days ago, I saw a news clip: a patient with high-level paraplegia used “thought” to control a robotic hand, steadily picking up a strawberry and bringing it to his mouth.
Not a sci-fi movie. A live demo at the Zhongguancun Forum.
I watched that clip several times. Hard to describe the feeling - something like “the future arrived but I wasn’t ready.”
What Happened Six Months Ago
In March 2026, “brain-computer interface” was written into China’s Government Work Report for the first time, listed alongside quantum technology, embodied intelligence, and 6G as one of six key future industries.
That’s a strong signal. Being in the Government Work Report means this is no longer an academic playground - it’s a national-level commitment.
Then on March 13, NeuroXess’s implantable BCI hand motor function compensation system received market approval from China’s National Medical Products Administration.
The world’s first approved invasive BCI Class III medical device. Not from the US. Not from Neuralink. From a Chinese company.
Money Followed
Policy dropped, capital followed immediately.
CITIC Securities data shows Q1 2026 BCI industry funding exceeded 4 billion yuan - already surpassing all of 2025. China’s CAICT projects the market will grow from 3 billion yuan in 2025 to 12 billion by 2030.
Quadrupling in four years is aggressive for hard tech.
And it’s not just money. On April 10, China released its first national BCI standards - reference architecture and multimodal data format specifications, effective August 1.
Standards matter. They signal the shift from “everyone doing their own thing” to “unified rules.” For companies, this means products can scale, enter hospitals, and get insurance coverage.
Beyond Medical
Most people hear “brain-computer interface” and think “helping paralyzed people move.” That’s the most mature application, yes.
But the possibilities extend far beyond.
Non-invasive BCI has already landed in consumer products: sleep regulation, mood intervention, children’s focus enhancement. Sounds like snake oil? I thought so too. But after reviewing clinical data, my stance shifted - at least for sleep monitoring, EEG accuracy genuinely outperforms wristbands by an order of magnitude.
Industrial applications are moving too. Power, metallurgy, petrochemical - high-risk industries are deploying BCI fatigue monitoring. Workers wear a headband, abnormal brainwaves trigger alerts. The business logic is clear: one accident costs more than thousands of headbands.
One direction that particularly fascinates me: Fudan University is developing an artificial retina, just 2mm by 2.5mm, with 4 human clinical trials completed. If this can be mass-produced… I don’t dare think too far ahead.
A Reality Check
After all the good news, some cold water.
BCI’s biggest challenge isn’t technology - it’s ethics and regulation. Implanting electrodes in human brains, no matter how mature the tech, faces enormous ethical scrutiny. Who has the right to read your brain signals? Where is the data stored? What if the device gets hacked?
No country has provided complete answers to these questions.
And between “written into the Government Work Report” and “actual mass commercialization,” there’s a long road. 2026 is being called the “year of scaled application,” but tech has had many such “year ones” that never delivered.
Still, I’m Optimistic
Not blindly - but because of concrete milestones:
The world’s first invasive device approved: a 0-to-1 breakthrough. National standards published: from chaos to order. Q1 funding exceeding the full previous year: capital voting with real money.
BCI probably won’t explode overnight like LLMs did. But it’s advancing in a more grounded way.
After all, helping a paralyzed patient pick up a strawberry again - from any angle, that deserves our serious attention.